This Week’s Infectious Disease Breaking News

Article

It was a week marked by significant FDA decisions and COVID-19 treatment updates.

It was a week marked by significant FDA decisions and COVID-19 treatment updates.

This week's top stories revolved around COVID-19 and potentially promising treatments. However, there were also some breaking FDA decisions.

COVID-19 Mutations Render All Monoclonal Antibody Treatments Ineffective

The last available COVID-19 monoclonal antibody, bebtelovimab, is now no longer authorized due to suspected inability to neutralize the most dominant COVID-19 variants, Omicron BQ.1.1 and BQ.1.

Did Overuse of Antibiotics Drive Secondary Infection in COVID-19 Patients?

COVID-19 hospital patients were prescribed 21.81% more antibiotics than patients without COVID-19. How did this affect their risk of coinfection?

Vitamin D Supplementation Appears to Offer Protective Benefits Against COVID-19

A new report finds veterans who took vitamin D supplements were less likely to get COVID-19 and less likely to die within 30 days of infection.

Looking Beyond C difficile: The Potential of the Gut Microbiome

Dr. Elizabeth Garner speculates the FDA approval of RBX2660 for recurrent C difficile infection will pave the way for more restorative microbiome therapies.

Shedding Light on Improvements in COVID-19 Inpatient Outcomes Over Time

A new study examining COVID-19 outcomes over time found evidence supporting the use of dexamethasone and raised concerns about using nonconcurrent controls in large platform trials.

FDA Authorizes Bivalent COVID-19 Vaccines for Children Down to 6 Months of Age

With an already overwhelming respiratory virus season with RSV and influenza, the hope is to prevent COVID-19 with these vaccines available to younger pediatric populations.

Newsletter

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.